Updated to include latest share prices, additional information on VIVUS and Analog Devices.
The stock was last quoted at $21.12, up 100%, on volume of 2.6 million, according to Nasdaq.com.
VIVUS said the committee voted 20-to-2 in favor of making the recommendation for approval based on a "favorable benefit-risk profile."The company noted that the recommendation doesn't guarantee the drug will receive approval from the FDA. Rather the guidance will be considered when the FDA reviews the company's new drug application for Qnexa, which was submitted in October 2011. A previous bid for approval of Qnexa failed because of health safety concerns. Even before Wednesday's news, VIVUS shares were on a roll, rising nearly 40% in the past year based on the regular-session close at $10.55, and hitting a 52-week high of $13.18 on Feb. 7. Wall Street had a bearish lean on the company ahead of the report with eight of the 14 analysts covering the stock at hold (6) or sell (2), although the median 12-month price target sits at $14.
Limited BrandsShares of Limited Brands (LTD) fell in late trades after the fashion apparel retailer gave a below-consensus outlook for the current quarter. The Columbus, Ohio-based company, whose brands include Victoria's Secret and Bath & Body Works, sees earnings of 35 to 40 cents a share for its fiscal first quarter ending in April. That's below the current average estimate of analysts polled by Thomson Reuters for a profit of 44 cents a share in the three-month period. For fiscal 2012, Limited forecast earnings of $2.60 to $2.80 a share vs. the consensus view for a profit of $2.91 a share. The disappointing outlook comes despite the company saying it now sees same-store sales for February rising in the mid to high single digit range on a percentage basis, up from a prior forecast for an increase in the low single digits.
The stock was last quoted at $44.12, down 3%, on volume of more than 260,000, according to Nasdaq.com. Based on Wednesday's regular session close at $45.48, the shares are up nearly 14% so far in 2012, and more than 40% in the past year, hitting a 52-week high of $46.70 on Feb. 16. For its fourth quarter ended in January, Limited reported an adjusted profit oif $1.50 a share, ahead of Wall Street's view for earnings of $1.46 a share. The company also said after the bell that it had completed a $250 million stock buyback program, and that its board has approved an additional $500 million repurchase authorization. The sell side had some reservations about Limited shares ahead of the report with 13 of the 24 analysts covering the stock at either hold (12) or underperform (1), and the stock was bumping up against the median 12-month price target of $46. In addition, the shares had made strong moves above both the 50-day and 200-day moving averages of $42.35 and $40.44, respectively. The forward price-to-earnings multiple stands at 15.6X at current levels vs. 12.8X for a competitor like Gap (GPS), which reports its quarterly results on Thursday, and 13.1 for the S&P 500.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV